EverHint – EMA 10 + Price + MACD – Top 9 Signals for Aug 14, 2026
Excerpt: 9 signals. Healthcare leads (2). price range $16-$514. 1 with insider buying.
What This Signal Is
Experimental strategy combining price crossing above EMA10 from below with MACD Line crossing above Signal Line from below. Both conditions must occur on the same day for a signal, providing double confirmation and higher-quality setups.
Entry Criteria:
- Buy: Price > EMA10 AND MACD line crosses above signal line
- Sell: Price < EMA10 AND MACD line crosses below signal line
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh signal: All conditions met on today's close
Holding period: 1-3 weeks | Risk level: Medium-High
Market Context
Equity markets are experiencing mild, broad-based selling pressure on August 14, 2026, with all three major indices declining modestly — the S&P 500, Nasdaq, and Dow Jones each off less than a third of a percent. This shallow pullback suggests a market consolidating near elevated levels rather than undergoing a meaningful trend reversal, which is a constructive backdrop for momentum-based strategies like EMA/MACD crossover signals. When price action is orderly and directional bias remains intact, trend-following signals tend to generate cleaner entries with less noise-driven whipsaw risk.
Volatility conditions are notably supportive, with the VIX sitting at 14.25 and falling 2.6% on the day. This low-volatility environment compresses intraday price swings, meaning signals generated by EMA and MACD crossovers are more likely to reflect genuine trend shifts rather than reactive spikes. However, traders should remain mindful that low VIX readings can precede sudden volatility expansions — position sizing and stop discipline become especially important when complacency is priced into the market.
Healthcare emerging as the top sector for today's signals is noteworthy from a rotation standpoint. Healthcare tends to attract capital during periods of mild risk-off sentiment or late-cycle positioning, and its relative strength here aligns with the slight defensive tilt suggested by today's broader market dip. This sector's typically stable earnings profile makes it more responsive to technical trend signals, as price movements are less susceptible to the sentiment-driven volatility that can undermine momentum strategies in more cyclical areas of the market.
🟢 Buy Signals (9 of 9 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | ALNY | Alnylam Pharmaceutical... | Healthcare | $228.65 | — | $30.6B |
| 2 | AMD | Advanced Micro Devices... | Technology | $514.39 | — | $838.8B |
| 3 | CC | The Chemours Company | Basic Materials | $15.85 | Buy +$80,552 | $2.4B |
| 4 | DTM | DT Midstream, Inc. | Energy | $136.90 | — | $14.0B |
| 5 | ETON | Eton Pharmaceuticals, ... | Healthcare | $58.86 | — | $1.6B |
| 6 | FCEL | FuelCell Energy, Inc. | Industrials | $22.37 | — | $1.8B |
| 7 | RDDT | Reddit, Inc. | Communication Services | $177.97 | — | $34.3B |
| 8 | TXT | Textron Inc. | Industrials | $89.00 | — | $15.3B |
| 9 | VIST | Vista Energy, S.A.B. d... | Energy | $68.31 | — | $7.1B |
Field Notes
Sector concentration: Healthcare (2), Energy (2), Industrials (2)
Insider buying (7d): CC (The Chemours Company, +$80,552)
Data coverage: 11.1% insider (7d), 0.0% congressional (30d), 0.0% earnings, 55.6% news (7d)
Peer Analysis
FCEL (FuelCell Energy, Inc.): Leads 4 peers: DFLI ($1.28), NEOV ($3.63), RGP ($4.22), ALTG ($7.23)
RDDT (Reddit, Inc.): Leads 5 peers: BIDU ($103.67), TME ($8.84), LLYVK ($108.86), LYV ($188.46), NBIS ($277.68)
VIST (Vista Energy, S.A.B. de C.V.): Leads 5 peers: MTDR ($53.69), CNX ($35.72), CHRD ($137.32), CRC ($53.31), MGY ($26.24)
ETON (Eton Pharmaceuticals, Inc.): Leads 5 peers: FULC ($3.74), NMRA ($1.60), LXRX ($2.32), OMER ($17.19), OCGN ($1.35)
DTM (DT Midstream, Inc.): Leads 5 peers: PAA ($23.90), VNOM ($42.29), AM ($22.55), DINO ($93.67), AR ($37.37)
Recent Headlines
ALNY (Alnylam Pharmaceuticals, Inc.)
- NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
AMD (Advanced Micro Devices, Inc.)
- Broadcom Sinks 6% as BofA Flags $370B in AI Debt, AMD Climbs 4% on Baird's $1,250 Call
- China Fears Affect Nividia and AMD in Very Different Ways
- AMD's Massive Upside: Why One Analyst Sees 160% Price Appreciation Ahead Following a Tough Month
- Here's What Jim Cramer Is Saying About Semis in August
- AMD: Why I'm Not Worried About The Multiple
CC (The Chemours Company)
- Chemours Expands Low-GWP Refrigerant Portfolio for Data Centers
ETON (Eton Pharmaceuticals, Inc.)
- Why Eton Pharmaceuticals Is Top of the Class Today
- Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These
FCEL (FuelCell Energy, Inc.)
- FuelCell Stock is Trending: A Key Level Just Came Into Play
Vlad's Take
Today's signals: 1 signal with insider buying adds conviction.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If you found this useful, a quick like, share, or subscribe keeps EverHint moving forward.